Library
BCM-95® (CURCUGREEN®), 29 Jan 2021
Published on : 2014
Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study
Adrian L Lopresti 1, Michael Maes 2, Garth L Maker 3, Sean D Hood 4, Peter D Drummond 5
25046624 DOI: 10.1016/j.jad.2014.06.001
Background: Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the treatment of depressive symptoms in individuals with major depressive disorder.
Methods: In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI).
Results: From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.
Conclusions: Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.
Limitations: Investigations with larger sample sizes, over extended treatment periods, and with varying curcumin dosages are required.
Keywords: Antidepressant; Clinical trial; Curcumin; Depression; Turmeric.
Copyright © 2014 Elsevier B.V. All rights reserved.
Keywords
- BCM-95
- bcm95
- clinical trial
- Curcumin
- depression
- turmeric extract
Request More Information
Increase your business growth potential with our patented extracts
Let’s collaborate to refine your ideas or built from scratch
Arjuna Natural
Arjuna Natural is India’s leading manufacturer and exporter of standardized botanical extracts for pharmaceutical and nutraceutical industries for more than two decades. Established in 1989, the company has grown...Read More
